Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Japan Hematopoietic Stem Cell Transplantation Market

ID: MRFR/LS/48279-HCR
200 Pages
Satyendra Maurya
Last Updated: April 24, 2026

Japan Hematopoietic Stem Cell Transplantation Market Research Report: Size, Share, Trend Analysis By Transplant Type (Allogeneic, Autologous), By Indication (Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Other Non-Malignant Disorders) and By Applications (Bone Marrow Transplant, Peripheral Blood Stem Cells Transplant, Cord Blood Transplant) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Japan Hematopoietic Stem Cell Transplantation Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Food, Beverages & Nutrition, BY Transplant Type (USD Million)
  49.     4.1.1 Allogeneic
  50.     4.1.2 Autologous
  51.   4.2 Food, Beverages & Nutrition, BY Indication (USD Million)
  52.     4.2.1 Acute Myeloid Leukemia
  53.     4.2.2 Acute Lymphoblastic Leukemia
  54.     4.2.3 Hodgkin Lymphoma
  55.     4.2.4 Non-Hodgkin Lymphoma
  56.     4.2.5 Multiple Myeloma
  57.     4.2.6 Other Non-Malignant Disorders
  58.   4.3 Food, Beverages & Nutrition, BY Application (USD Million)
  59.     4.3.1 Bone Marrow Transplant
  60.     4.3.2 Peripheral Blood Stem Cells Transplant
  61.     4.3.3 Cord Blood Transplant
  62. 5 SECTION V: COMPETITIVE ANALYSIS
  63.   5.1 Competitive Landscape
  64.     5.1.1 Overview
  65.     5.1.2 Competitive Analysis
  66.     5.1.3 Market share Analysis
  67.     5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  68.     5.1.5 Competitive Benchmarking
  69.     5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  70.     5.1.7 Key developments and growth strategies
  71.       5.1.7.1 New Product Launch/Service Deployment
  72.       5.1.7.2 Merger & Acquisitions
  73.       5.1.7.3 Joint Ventures
  74.     5.1.8 Major Players Financial Matrix
  75.       5.1.8.1 Sales and Operating Income
  76.       5.1.8.2 Major Players R&D Expenditure. 2023
  77.   5.2 Company Profiles
  78.     5.2.1 Novartis (CH)
  79.       5.2.1.1 Financial Overview
  80.       5.2.1.2 Products Offered
  81.       5.2.1.3 Key Developments
  82.       5.2.1.4 SWOT Analysis
  83.       5.2.1.5 Key Strategies
  84.     5.2.2 Bristol-Myers Squibb (US)
  85.       5.2.2.1 Financial Overview
  86.       5.2.2.2 Products Offered
  87.       5.2.2.3 Key Developments
  88.       5.2.2.4 SWOT Analysis
  89.       5.2.2.5 Key Strategies
  90.     5.2.3 Amgen (US)
  91.       5.2.3.1 Financial Overview
  92.       5.2.3.2 Products Offered
  93.       5.2.3.3 Key Developments
  94.       5.2.3.4 SWOT Analysis
  95.       5.2.3.5 Key Strategies
  96.     5.2.4 Gilead Sciences (US)
  97.       5.2.4.1 Financial Overview
  98.       5.2.4.2 Products Offered
  99.       5.2.4.3 Key Developments
  100.       5.2.4.4 SWOT Analysis
  101.       5.2.4.5 Key Strategies
  102.     5.2.5 Celgene (US)
  103.       5.2.5.1 Financial Overview
  104.       5.2.5.2 Products Offered
  105.       5.2.5.3 Key Developments
  106.       5.2.5.4 SWOT Analysis
  107.       5.2.5.5 Key Strategies
  108.     5.2.6 Takeda (JP)
  109.       5.2.6.1 Financial Overview
  110.       5.2.6.2 Products Offered
  111.       5.2.6.3 Key Developments
  112.       5.2.6.4 SWOT Analysis
  113.       5.2.6.5 Key Strategies
  114.     5.2.7 Roche (CH)
  115.       5.2.7.1 Financial Overview
  116.       5.2.7.2 Products Offered
  117.       5.2.7.3 Key Developments
  118.       5.2.7.4 SWOT Analysis
  119.       5.2.7.5 Key Strategies
  120.     5.2.8 Merck (DE)
  121.       5.2.8.1 Financial Overview
  122.       5.2.8.2 Products Offered
  123.       5.2.8.3 Key Developments
  124.       5.2.8.4 SWOT Analysis
  125.       5.2.8.5 Key Strategies
  126.     5.2.9 AstraZeneca (GB)
  127.       5.2.9.1 Financial Overview
  128.       5.2.9.2 Products Offered
  129.       5.2.9.3 Key Developments
  130.       5.2.9.4 SWOT Analysis
  131.       5.2.9.5 Key Strategies
  132.   5.3 Appendix
  133.     5.3.1 References
  134.     5.3.2 Related Reports
  135. 6 LIST OF FIGURES
  136.   6.1 MARKET SYNOPSIS
  137.   6.2 JAPAN MARKET ANALYSIS BY TRANSPLANT TYPE
  138.   6.3 JAPAN MARKET ANALYSIS BY INDICATION
  139.   6.4 JAPAN MARKET ANALYSIS BY APPLICATION
  140.   6.5 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
  141.   6.6 RESEARCH PROCESS OF MRFR
  142.   6.7 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
  143.   6.8 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
  144.   6.9 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
  145.   6.10 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
  146.   6.11 FOOD, BEVERAGES & NUTRITION, BY TRANSPLANT TYPE, 2024 (% SHARE)
  147.   6.12 FOOD, BEVERAGES & NUTRITION, BY TRANSPLANT TYPE, 2024 TO 2035 (USD Million)
  148.   6.13 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 (% SHARE)
  149.   6.14 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 TO 2035 (USD Million)
  150.   6.15 FOOD, BEVERAGES & NUTRITION, BY APPLICATION, 2024 (% SHARE)
  151.   6.16 FOOD, BEVERAGES & NUTRITION, BY APPLICATION, 2024 TO 2035 (USD Million)
  152.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  153. 7 LIST OF TABLES
  154.   7.1 LIST OF ASSUMPTIONS
  155.     7.1.1
  156.   7.2 Japan MARKET SIZE ESTIMATES; FORECAST
  157.     7.2.1 BY TRANSPLANT TYPE, 2025-2035 (USD Million)
  158.     7.2.2 BY INDICATION, 2025-2035 (USD Million)
  159.     7.2.3 BY APPLICATION, 2025-2035 (USD Million)
  160.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  161.     7.3.1
  162.   7.4 ACQUISITION/PARTNERSHIP
  163.     7.4.1

Japan Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Transplant Type (USD Million, 2025-2035)

  • Allogeneic
  • Autologous

Food, Beverages & Nutrition By Indication (USD Million, 2025-2035)

  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • Multiple Myeloma
  • Other Non-Malignant Disorders

Food, Beverages & Nutrition By Application (USD Million, 2025-2035)

  • Bone Marrow Transplant
  • Peripheral Blood Stem Cells Transplant
  • Cord Blood Transplant

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓